CD
EW icon

Chapin Davis’s Edwards Lifesciences EW Stock Holding History

Chapin Davis’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,610
Closed -$609K – 266
2026
Q1 		$609K Buy
7,610
+343
+5% +$28.3K 0.14% 137
2025
Q4 		$620K Buy
7,267
+645
+10% +$52.9K 0.15% 130
2025
Q3 		$515K Buy
6,622
+67
+1% +$5.24K 0.13% 146
2025
Q2 		$513K Sell
6,555
-310
-5% -$23.1K 0.14% 134
2025
Q1 		$498K Buy
6,865
+42
+0.6% +$3.01K 0.17% 124
2024
Q4 		$450K Hold
6,823
– – 0.15% 134
2024
Q3 		$450K Sell
6,823
-1,725
-20% -$125K 0.15% 135
2024
Q2 		$790K Hold
8,548
– – 0.27% 82
2024
Q1 		$817K Buy
8,548
+140
+2% +$11.8K 0.3% 85
2023
Q4 		$641K Buy
8,408
+100
+1% +$6.96K 0.27% 96
2023
Q3 		$576K Buy
8,308
+285
+4% +$22.9K 0.27% 91
2023
Q2 		$757K Sell
8,023
-122
-1% -$10.6K 0.36% 77
2023
Q1 		$674K Buy
8,145
+295
+4% +$23.2K 0.35% 81
2022
Q4 		$586K Buy
+7,850
New +$605K 0.34% 85

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Chapin Davis's EW Position: Q2 2026 in Review

Chapin Davis sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 7,610 shares — an estimated $609K sold.

Chapin Davis first reported a position in EW in Q4 2022 and held it in 14 quarters. The position peaked at $817K in Q1 2024. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Chapin Davis reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Chapin Davis sold 7,610 Edwards Lifesciences shares in Q2 2026, an estimated $609K.
  • Chapin Davis first reported a position in Edwards Lifesciences in Q4 2022 and held it in 14 quarters.
  • Chapin Davis's Edwards Lifesciences position peaked at $817K in Q1 2024.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.